Boston-based medical device company CereVasc has secured $85 million in a Series C financing round to advance its innovative treatment for neurological diseases. The funding, led by Piper Sandler Merchant Banking, will propel the company's eShunt System through final clinical trials and toward commercialization. This significant capital infusion underscores investor confidence in CereVasc's minimally invasive approach to treating hydrocephalus.
Strategic Investment for Clinical Advancement
The financing round was spearheaded by Piper Sandler Merchant Banking and attracted notable new strategic investors. Johnson & Johnson Innovation – JJDC, Inc., and Medtronic joined the round, signaling strong industry validation for CereVasc's technology. Continued support also came from existing investors, including Bain Capital Life Sciences and Perceptive Xontogeny Venture Funds.
Fueling the eShunt System's Path to Market
A primary allocation of the new capital will be to conclude the STRIDE pivotal trial for the eShunt System. This multi-center study is designed to assess the device's safety and effectiveness in patients with Normal Pressure Hydrocephalus. The results will form the basis of a future Premarket Approval (PMA) submission to the U.S. Food and Drug Administration.
Beyond clinical development, the proceeds will facilitate the company's operational scale-up and commercial readiness. These preparations are essential for a successful product launch in the United States upon potential regulatory approval. This strategic investment ensures CereVasc is well-positioned to transition from a clinical-stage to a commercial-stage organization.
A Novel Approach to Hydrocephalus Treatment
CereVasc's eShunt System represents a paradigm shift in treating communicating hydrocephalus, a condition involving excess cerebrospinal fluid. The device is implanted using a minimally invasive, endovascular technique, avoiding the need for traditional open-brain surgery. This innovative approach aims to reduce patient risk and improve outcomes compared to the current standard of care.
Bolstering Corporate Governance
Coinciding with the financing, CereVasc has significantly strengthened its Board of Directors with three key appointments. Kevin Conroy joins as Lead Independent Director, while Christopher Geyen will serve as an independent director and Chair of the Audit Committee. Tom Schnettler of Piper Sandler Merchant Banking also joins the board, representing the new Series C investors.
These new directors bring a wealth of experience in the medical device industry and corporate governance. Their expertise will be instrumental in guiding CereVasc through the critical phases of regulatory submission and market launch. The enhanced board structure reflects the company's commitment to robust leadership as it advances toward commercialization.
This $85 million financing marks a pivotal moment for CereVasc, providing the necessary resources to complete its clinical program and prepare for market entry. With strong backing from industry leaders and a fortified board, the company is poised to potentially revolutionize treatment for hydrocephalus patients. The successful development and commercialization of the eShunt System could offer a safer, less invasive alternative for a vulnerable patient population.